Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27678155 | 0.83 | SIGMAR1 (0.55) | ALDH1A1KDM4E | |
| SCHEMBL6860719 | 0.76 | ALDH1A1 (0.58) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL7500264 | 0.74 | ALDH1A1 (0.66) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL6901339 | 0.73 | DRD4 (0.60) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL3585542 | 0.73 | ALDH1A1 (1.00) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL8833523 | 0.72 | DRD4 (0.72) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL8357217 | 0.72 | ALDH1A1 (0.82) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL8834289 | 0.72 | DRD4 (1.00) | ALDH1A1TSHRDRD2DRD4DRD3 | |
| SCHEMBL18193014 | 0.71 | DRD2 (0.58) | DRD2DRD4DRD3KDM4E | |
| SCHEMBL8872544 | 0.70 | ALDH1A1 (0.78) | ALDH1A1TSHRDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2003-01-23 | — | — | US | claimed |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | claimed |
| US-6797824-B2 | UEFUL IN THE DIAGNOSIS AND THERAPY OF AFFECTIVE DISORDERS SUCH AS SCHIZOPHRENIA AND DEPRESSION AS WELL AS CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM | NEUROGEN CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2003-01-23 | — | — | US | disclosed |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6358955-B1 | SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS, PARKINSON*S DISEASE; ANTIDEPRESSANTS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6069251-A | HIGHLY SELECTIVE PARTIAL AGONISTS OR ANTAGONISTS AT BRAIN DOPAMINE RECEPTOR SUBTYPES OR PRODRUGS; DIAGNOSIS AND TREATMENT SCHIZOPHRENIA; ANTIDEPRESSANTS; CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM. | NEUROGEN CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-5712392-A | DOPAMINERGIC AGENTS TREATING SCHIZOPHRENIA, ANTIDEPRESSANTS FOR PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0793653-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-10 | — | — | EP | disclosed |
| US-5656762-A | TREATING SCHIZOPHRENIA, DEPRESSION, PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646281-A | FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5633377-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996016040-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | CHRNA4, GRIA4, OPRM1 | ALDH1A1 1608/4885TSHR 68/4885DRD2 22/4885 |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | DRD2, OPRM1, OPRD1 | ALDH1A1 1628/4885TSHR 98/4885DRD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.